Skip to main content Skip to section navigation Skip to footer
Inhibikase Therapeutics, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Science Advisors
  • Technology
    • Overview
    • RAMP™ Drug Innovation Engine
  • Pipeline
    • Overview
    • IkT-148009 for Parkinson’s Disease and GI complications
    • IkT-001Pro for CML
    • IkT-01427 for PML
    • Collaborative Programs
    • Partnering with Inhibikase
  • Scientific Publications
  • Clinical Trials
  • News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
  • Careers

Press Releases

News

News

  • Press Releases
Aug 23, 2022 8:00am EDT

Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease

Aug 12, 2022 4:55pm EDT

Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity

Aug 08, 2022 8:30am EDT

Inhibikase Therapeutics to Report Second Quarter 2022 Financial Results on August 12, 2022

Jun 13, 2022 8:00am EDT

Inhibikase Therapeutics Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review

May 16, 2022 5:00pm EDT

Inhibikase Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity

May 10, 2022 8:05am EDT

Inhibikase Therapeutics to Participate at the H.C. Wainwright Global Investment Conference

May 09, 2022 4:05pm EDT

Inhibikase Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022

Apr 21, 2022 4:05pm EDT

Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference

Apr 06, 2022 8:00am EDT

Inhibikase Therapeutics to Host Virtual KOL Investor Event on April 20, 2022

Mar 31, 2022 5:00pm EDT

Inhibikase Therapeutics Reports Full Year 2021 Financial Results and Highlights Recent Period Activity

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook
  • Visit us on Twitter
  • Visit us on Linkedin
  • Visit us on Youtube
©2023 Inhibikase Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap